Hardback
Biotechnology and Competitive Advantage
Europe’s Firms and the US Challenge
9781858987392 Edward Elgar Publishing
Biotechnology and Competitive Advantage investigates the development of biotechnology in Europe and the United States. It examines why Europe has fallen behind in applying biotechnology, when its scientific capabilities are largely comparable to those in the US. In addition it sheds new light on the wider context of the theory of growth of new technologies.
More Information
Critical Acclaim
Contributors
Contents
More Information
Biotechnology and Competitive Advantage investigates the development of biotechnology in Europe and the United States. It examines why Europe has fallen behind in applying biotechnology, when its scientific capabilities are largely comparable to those in the US. In addition it sheds new light on the wider context of the theory of growth of new technologies.
This innovative book brings together a wide range of material concerning socio-economic aspects of the development of biotechnology in Europe and the US. Issues discussed include:
• European policy for biotechnology, in individual countries and at the European Union level
• risk regulation and the ways in which industry, regulators and non-government organizations manage risk regulation and the perception of risk
• the formation and roles of biotechnology firms in Europe and the US and their relative capabilities
• gene therapy development in Europe and the US
• the impact on Europe of overseas biotechnology research by European multinationals.
This book argues in favour of developing an integrated research and development system which will strengthen the research and development capabilities of all the actors involved.
This book will be of great interest to science policymakers; businesses and academics studying the development of biotechnology and students of economics and business studies throughout Europe and the US.
This innovative book brings together a wide range of material concerning socio-economic aspects of the development of biotechnology in Europe and the US. Issues discussed include:
• European policy for biotechnology, in individual countries and at the European Union level
• risk regulation and the ways in which industry, regulators and non-government organizations manage risk regulation and the perception of risk
• the formation and roles of biotechnology firms in Europe and the US and their relative capabilities
• gene therapy development in Europe and the US
• the impact on Europe of overseas biotechnology research by European multinationals.
This book argues in favour of developing an integrated research and development system which will strengthen the research and development capabilities of all the actors involved.
This book will be of great interest to science policymakers; businesses and academics studying the development of biotechnology and students of economics and business studies throughout Europe and the US.
Critical Acclaim
‘I found that this volume presented a good many facts and some interesting analyses of the biotechnology industries of Europe and America . . . I suspect that policymakers and business managers will also find the factual base and discussions in this volume to be a catalyst for clearer thinking about a number of issues which confront them.’
– John W. Medcof, R&D Management
‘Based on a broad theoretical foundation and broad empirical evidence gathered with different methodologies and tools, it provides many insights into the state of biotechnology in Europe and many suggestions for political measures. Viewed as a whole, this book is rewarding reading for researchers, management practitioners and policymakers.’
– Andre Jungmittag, Research Policy
‘The book gives lots of interesting information on venture capital biotechnology companies. . .’
– Parvinder Chawla, Journal of Scientific and Industrial Research
– John W. Medcof, R&D Management
‘Based on a broad theoretical foundation and broad empirical evidence gathered with different methodologies and tools, it provides many insights into the state of biotechnology in Europe and many suggestions for political measures. Viewed as a whole, this book is rewarding reading for researchers, management practitioners and policymakers.’
– Andre Jungmittag, Research Policy
‘The book gives lots of interesting information on venture capital biotechnology companies. . .’
– Parvinder Chawla, Journal of Scientific and Industrial Research
Contributors
Contributors: R. Acharya, J. Chataway, P. Martin, P. Saviotti, J. Senker, R. van Vliet
Contents
Contents: 1. Introduction (R. van Vilet) 2. Biotechnology: the external environment (J. Senker) 3. Industrial Structure and the Dynamics of Knowledge Generation in Biotechnology (P.P. Saviotti) 4. Risk Perception, Regulation and the Management of Agro-biotechnologies (J. Chataway and G. Assouline) 5. The Creation of European Dedicated Biotechnology Firms (P.P. Saviotti, P.-B. Joly, J. Estades, S. Ramani and M.-A. de Looze) 6. The Evolution of European Biotechnology and its future Competitiveness (R. Acharya, A. Arundel and L. Orsenigo) 7. Biotechnology and Europe’s chemical/pharmaceutical Multinationals (J. Senker, P.-B. Joly and M. Reinhard) 8. The ‘Commercialization Gap’ in Gene Therapy: Lessons for European Competitiveness (P. Martin and S. Thomas) 9. Conclusions – Biotechnology and European Competitiveness (R. Acharya) Bibliography
